search
Back to results

Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms

Primary Purpose

Aneurysms, Arteriovenous Malformations

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
minocycline
doxycycline
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aneurysms focused on measuring giant aneurysms, arteriovenous malformations, minocycline, doxycycline, BAVM

Eligibility Criteria

13 Years - 80 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Giant aneurysms or brain arteriovenous malformations (BAVM) Female patients of child bearing age using effective birth control, males Creatinine no greater than 2.0 mg/dl ALT no greater than 2 times upper limit of control Exclusion Criteria: Unstable medical illness Contraindications to Tetracycline History of vestibular disease, (except benign positional vertigo) Prior tetracycline use within 2 mos of baseline visit. History of noncompliance with treatment or other protocols History of systemic lupus Patients not eligible for MRI

Sites / Locations

  • University of California

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Brain AVMs

Aneurysms

Arm Description

This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.

Outcomes

Primary Outcome Measures

MRI will be done baseline and post treatment.
MMP levels are being followed q 6-mos.
Drug levels are being followed q 6-mos.

Secondary Outcome Measures

Full Information

First Posted
October 24, 2005
Last Updated
October 8, 2013
Sponsor
University of California, San Francisco
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00243893
Brief Title
Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms
Official Title
Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
July 2004 (undefined)
Primary Completion Date
October 2008 (Actual)
Study Completion Date
October 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this pilot study is to investigate the use of minocycline and doxycycline as medical therapy for inoperable or partially treated arteriovenous malformations (AVMs) and giant aneurysms.
Detailed Description
Arteriovenous malformations (AVMs) are a treatable cause of stroke in young adults. The processes by which AVMs and giant aneurysms grow in size and spontaneously bleed are unknown. The primary reason to treat AVMs and aneurysms is to guard against intracranial bleeding. This pilot study will examine the use of two common antibiotics-minocycline and doxycycline-as medical therapy for inoperable or partially treated AVMs and giant aneurysms. These drugs, which are tetracycline derivatives, can reduce the levels of a family of enzymes, called matrix metalloproteases, that degrade tissue and thereby cause a reduction in the risk of spontaneous bleeding from AVMs or aneurysm-which is the main cause of stroke associated with these disorders. The enzymes can contribute to weaknesses in the wall of blood vessels and may increase the risk of the vessel wall rupturing and causing spontaneous bleeding. This trial also will show that taking minocycline and doxycycline over an extended period in this patient population is safe and well tolerated. Results from this study could help plan future studies to benefit patients with abnormal blood vessels prone to bleeding in their brains.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aneurysms, Arteriovenous Malformations
Keywords
giant aneurysms, arteriovenous malformations, minocycline, doxycycline, BAVM

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Brain AVMs
Arm Type
Active Comparator
Arm Description
This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.
Arm Title
Aneurysms
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
minocycline
Intervention Description
Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Intervention Type
Drug
Intervention Name(s)
doxycycline
Intervention Description
Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Primary Outcome Measure Information:
Title
MRI will be done baseline and post treatment.
Time Frame
2 years
Title
MMP levels are being followed q 6-mos.
Time Frame
Patients called weekly for 1st-3 months, then every 6-months until completion of study
Title
Drug levels are being followed q 6-mos.
Time Frame
Patients called weekly for 1st-3 months, then every 6-months until completion of study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Giant aneurysms or brain arteriovenous malformations (BAVM) Female patients of child bearing age using effective birth control, males Creatinine no greater than 2.0 mg/dl ALT no greater than 2 times upper limit of control Exclusion Criteria: Unstable medical illness Contraindications to Tetracycline History of vestibular disease, (except benign positional vertigo) Prior tetracycline use within 2 mos of baseline visit. History of noncompliance with treatment or other protocols History of systemic lupus Patients not eligible for MRI
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William L. Young, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
18212521
Citation
Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT, Guglielmo BJ, McCulloch CE, Young WL. Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis. 2008;25(1-2):157-63. doi: 10.1159/000113733. Epub 2008 Jan 23.
Results Reference
result
Links:
URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605012/
Description
Related Info

Learn more about this trial

Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms

We'll reach out to this number within 24 hrs